Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

The New England journal of medicine - 13 Jul 2023

Tsuboi Masahiro, Herbst Roy S, John Thomas, Kato Terufumi, Majem Margarita, Grohé Christian, Wang Jie, Goldman Jonathan W, Lu Shun, Su Wu-Chou, de Marinis Filippo, Shepherd Frances A, Lee Ki Hyeong, Le Nhieu Thi, Dechaphunkul Arunee, Kowalski Dariusz, Poole Lynne, Bolanos Ana, Rukazenkov Yuri, Wu Yi-Long

Abstract excerpt

BACKGROUND: Among patients with resected, epidermal growth factor receptor (EGFR)-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or without previous adjuvant chemotherapy, resulted in significantly longer disease-free survival than placebo in the ADAURA trial. We report the results of the planned final analysis of overall survival. METHODS: In this phase 3,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to COVID-19

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Survival Analysis

Source

Identifiers

PMID: 37272535
DOI: 10.1056/NEJMoa2304594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.PMID 37272535Read ↗

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Semantic proximity Read ↗

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.Semantic proximity Read ↗

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.Semantic proximity Read ↗

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.Semantic proximity Read ↗

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.Semantic proximity Read ↗

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.Semantic proximity Read ↗

Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).Semantic proximity Read ↗

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.Semantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.